Rhythm Pharmaceuticals Inc. (RYTM)

Schlusskurs vom Vortag:

$40.98

Offen:

$42.49

24-Stunden-Volumen:

247.93K

Marktkapitalisierung:

$2.62B

Einnahmen:

$77.43M

Nettoeinkommen (Verlust:

$-184.68M

KGV:

-13.10

EPS:

-3.28

Netto-Cashflow:

$-136.20M

1W Leistung:

+12.17%

1M Leistung:

+5.01%

6M Leistung:

+59.21%

1J Leistung:

+131.86%

1-Tages-Spanne:

$41.86

$43.61

52-Wochen-Spanne:

$15.50

$52.57

Rhythm Pharmaceuticals Inc. Stock (RYTM) Company Profile

Firmenname

Rhythm Pharmaceuticals Inc.

Sektor

Healthcare (1223)

Branche

Biotechnology (681)

Telefon

857-264-4280

Adresse

500 Boylston Street, 11th Floor, Boston, MA

Mitarbeiter

43

Twitter

@rhythmpharma

Nächster Verdiensttermin

2024-05-14

Neueste SEC-Einreichungen

RYTM's Discussions on Twitter

Rhythm Pharmaceuticals Inc. Stock (RYTM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-08-01	Hochstufung	BofA Securities	Neutral → Buy
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-08-08	Hochstufung	Goldman	Neutral → Buy
2022-08-05	Hochstufung	BofA Securities	Underperform → Neutral
2022-06-17	Bestätigt	Needham	Buy
2022-03-02	Fortgesetzt	Stifel	Buy
2022-02-17	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2021-12-08	Eingeleitet	Wells Fargo	Overweight
2021-11-19	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-14	Fortgesetzt	Goldman	Neutral
2021-08-04	Herabstufung	BofA Securities	Neutral → Underperform
2021-08-04	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2020-11-30	Herabstufung	BofA Securities	Buy → Neutral
2020-01-08	Eingeleitet	Goldman	Sell
2019-07-12	Hochstufung	Stifel	Hold → Buy
2019-07-08	Eingeleitet	Canaccord Genuity	Buy
2019-03-13	Eingeleitet	Ladenburg Thalmann	Buy
2018-09-07	Fortgesetzt	Morgan Stanley	Overweight
2018-06-25	Bestätigt	Needham	Buy
2018-06-15	Bestätigt	Needham	Buy
2017-10-30	Eingeleitet	BofA/Merrill	Buy
2017-10-30	Eingeleitet	Needham	Buy

Alle ansehen

Rhythm Pharmaceuticals Inc. Aktie (RYTM) Neueste Nachrichten

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

Zacks Investment Research

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

GlobeNewswire Inc.

Analyst Expectations For Rhythm Pharmaceuticals's Future

Benzinga

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

GlobeNewswire Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

GlobeNewswire Inc.

Finanzdaten der Rhythm Pharmaceuticals Inc.-Aktie (RYTM)

Rhythm Pharmaceuticals Inc. (RYTM) Umsatz 2024

Rhythm Pharmaceuticals Inc. (RYTM) Nettogewinn 2024

Rhythm Pharmaceuticals Inc. (RYTM) Free Cashflow 2024

Rhythm Pharmaceuticals Inc. (RYTM) Gewinn je Aktie 2024